Observational Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Oct 21, 2017; 23(39): 7139-7149
Published online Oct 21, 2017. doi: 10.3748/wjg.v23.i39.7139
Table 4 Correlations between the scores of clinimetric tests for articular-gastrointestinal activity and patient reported outcomes of health-related quality of life scores
CDAIpMAYOIBDQBASDAIBASFIASDAS-CRPPtGAHAQSf-36/ PCSSf-36/ MCSCRP
At baseline
CDAI11-0.57b0.190.290.210.140.12-0.24-0.330.35
pMAYO11-0.48a0.340.380.370.150.18-0.14-0.110.28
IBDQ-0.57b-0.48a1-0.38b-0.34a-0.52b-0.26-0.190.270.67b-0.26
BASDAI0.190.34-0.38b10.64b0.69b0.240.26-0.22-0.31a0.00
BASFI0.290.38-0.34a0.64b10.57b0.37b0.36b-0.44b-0.150.37b
ASDAS-CRP0.210.37-0.52b0.69b0.57b10.37b0.36b-0.30a-0.41b0.32a
PtGA0.140.15-0.260.240.37b0.37b10.22-0.14-0.220.14
HAQ0.120.18-0.190.260.36b0.36b0.221-0.46b-0.030.07
Sf-36/PCS-0.24-0.140.27-0.22-0.44e-0.30a-0.14-0.46b10.05-0.13
Sf-36/MCS-0.33-0.110.67b-0.31a-0.15-0.41b-0.22-0.030.051-0.08
After 12 mo of therapy with adalimumab (ES-AN/Ada cohort)
CDAI11-0.83b0.160.56a0.54a0.53a0.53a-0.71b-0.67b0.75b
pMAYO11-0.510.180.490.170.56-0.29-0.14-0.250.6
IBDQ-0.83b-0.511-0.23-0.56b-0.55b-0.61b-0.36a0.53b0.66b-0.52b
BASDAI0.160.18-0.2310.58b0.68b0.51b0.39a-0.52b-0.11-0.14
BASFI0.56a0.49-0.56b0.58b10.56b0.64b0.54b-0.52b-0.45a0.16
ASDAS-CRP0.54a0.17-0.55b0.68b0.56b10.67b0.38a-0.62b-0.41a0.31
PtGA0.53a0.56-0.61b0.51b0.64b0.67b10.51b-0.37a-0.59b0.26
HAQ0.53a-0.29-0.36a0.39a0.54b0.38a0.51b1-0.47b-0.40a0.10
Sf-36/PCS11-0.83b0.160.56a0.54a0.53a0.53a-0.71b-0.67b0.75b
Sf-36/MCS11-0.510.180.490.170.56-0.29-0.14-0.250.60
CRP-0.83b-0.511-0.23-0.56b-0.55b-0.61b-0.36a0.53b0.66b-0.52b